Phase 2 biotech developing therapies for NASH and type 2 diabetes.
Industry: Health Care
First Day Return: -8.1%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 09/28/2018 |
Offer Price | $16.00 |
Price Range $14.00 - $16.00 | |
Offer Shares (mm) | 6.7 |
Deal Size ($mm) | $107 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 04/03/2019 |
Offer Price | IPO Intelligence Only |
Price Range | IPO Intelligence Only |
Offer Shares (mm) | IPO Intelligence Only |
Deal Size ($mm) | $107 |
Lock-Up Date | IPO Intelligence Only |
Street Research | IPO Intelligence Only |
Underwriters |
---|
IPO Intelligence Only |
Company Data | |
---|---|
Headquarters | South San Francisco, CA, United States |
Founded | 2007 |
Employees at IPO | 153 |
Website www.ngmbio.com |